Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments (Aquisition of CyDex) (Details)

v2.4.0.8
Financial Instruments (Aquisition of CyDex) (Details) (Cydex Pharmaceuticals, Inc, USD $)
In Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2013
Contingent Consideration Classified as Equity
Dec. 31, 2013
Minimum
Contingent Consideration Classified as Equity
Dec. 31, 2013
Maximum
Contingent Consideration Classified as Equity
Dec. 31, 2014
Scenario, Forecast
Contingent Consideration Classified as Equity
Dec. 31, 2014
Scenario, Forecast
Minimum
Contingent Consideration Classified as Equity
Dec. 31, 2014
Scenario, Forecast
Maximum
Contingent Consideration Classified as Equity
Credit Derivatives [Line Items]              
Range of annual revenue subject to revenue sharing     $ 4.2 [1] $ 19.8 [1]   $ 5.1 [1] $ 17.9 [1]
Revenue volatility   25.00%     25.00%    
Average of probability of commercialization   67.60%     67.40%    
Sales beta   0.60     0.60    
Credit rating   BBB     BBB    
Equity risk premium   6.00%     6.00%    
Amount Of Revenue For Contingent Consideration $ 15            
[1] Revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement.